Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2021

View Archived Issues

Axcella Health initiates phase II EMMPOWER study of AXA-1665

Phase I/II study evaluates CD19 and BCMA CAR T cells in patients with acute leukemia

Basket evaluation of atezolizumab with BDB-001 and radiotherapy in multiple solid tumors

Olix initiates phase II study of OLX-10010 as treatment of hypertrophic scars

Avidity advances preclinical programs in DMD and myotonic dystrophy type 1

In vivo model developed for evaluating the cytokine release toxicity of bispecific antibodies

KIF13B linked to progression of wet age-related macular degeneration

C4 Therapeutics and Roche patent new PROTACs

Corbus Pharmaceuticals divulges cannabinoid CB2 receptor agonists

First patients dosed in phase I study of PBI-100

Biogen identifies BTK inhibitors

New DHODH inhibitors synthesized by Janssen

JD Bioscience presents 5-HT2A receptor antagonists

Phase Ib data for cagrilintide plus semaglutide in overweight or obese subjects

Incyte initiates phase II study of INCB-054707 in nonsegmental vitiligo

BBP-711 enters phase I healthy volunteer study

Phase I study evaluates gene therapy AAV9/CLN7 in Batten disease

ChAdOx1 nCoV-19 vaccine shows efficacy against the B.1.1.7 variant of SARS-CoV-2

AACR 2021: Iron fist could make for less toxic cancer drug

Medivir reports phase II data on remetinostat in squamous cell carcinoma

Phase I trial evaluates bispecific antibody TNB-585 in metastatic CRPC

SPECTRA and PULSAR studies on sotatercept for treating PAH show promise

Giiant uses seed financing to initiate IND-enabling studies with GT-2108 for ulcerative colitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...